KR100875800B1 - 이소플라본과 다가 불포화 지방산의 혼합물을 포함하는골다공증 예방용 조성물 - Google Patents
이소플라본과 다가 불포화 지방산의 혼합물을 포함하는골다공증 예방용 조성물 Download PDFInfo
- Publication number
- KR100875800B1 KR100875800B1 KR1020037012046A KR20037012046A KR100875800B1 KR 100875800 B1 KR100875800 B1 KR 100875800B1 KR 1020037012046 A KR1020037012046 A KR 1020037012046A KR 20037012046 A KR20037012046 A KR 20037012046A KR 100875800 B1 KR100875800 B1 KR 100875800B1
- Authority
- KR
- South Korea
- Prior art keywords
- vitamin
- composition
- acid
- concentration
- group
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 title claims abstract description 26
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 15
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 235000008696 isoflavones Nutrition 0.000 title claims abstract description 14
- 230000002265 prevention Effects 0.000 title claims 2
- 150000002515 isoflavone derivatives Chemical class 0.000 title description 12
- 239000011712 vitamin K Substances 0.000 claims abstract description 38
- 235000019168 vitamin K Nutrition 0.000 claims abstract description 38
- 229930003448 Vitamin K Natural products 0.000 claims abstract description 35
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims abstract description 35
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 35
- 239000011710 vitamin D Substances 0.000 claims abstract description 35
- 150000003721 vitamin K derivatives Chemical class 0.000 claims abstract description 35
- 229940046010 vitamin k Drugs 0.000 claims abstract description 35
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 33
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 32
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 32
- 229940046008 vitamin d Drugs 0.000 claims abstract description 32
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims abstract description 28
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims abstract description 25
- 235000006539 genistein Nutrition 0.000 claims abstract description 23
- 229940045109 genistein Drugs 0.000 claims abstract description 23
- 230000011164 ossification Effects 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 241000124008 Mammalia Species 0.000 claims abstract description 10
- 235000007882 dietary composition Nutrition 0.000 claims abstract description 10
- 230000003405 preventing effect Effects 0.000 claims abstract description 10
- 230000004936 stimulating effect Effects 0.000 claims abstract description 9
- 239000002671 adjuvant Substances 0.000 claims abstract description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 5
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 claims abstract description 4
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 claims abstract description 4
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims abstract description 4
- ZWSNUPOSLDAWJS-QNDFHXLGSA-N 6,7-dihydroxy-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one Chemical compound OC[C@H]1O[C@@H](Oc2ccc(cc2)-c2coc3cc(O)c(O)cc3c2=O)[C@H](O)[C@@H](O)[C@@H]1O ZWSNUPOSLDAWJS-QNDFHXLGSA-N 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 31
- 210000000988 bone and bone Anatomy 0.000 claims description 17
- 239000012141 concentrate Substances 0.000 claims description 11
- 239000011772 phylloquinone Substances 0.000 claims description 11
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 10
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 9
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000007903 gelatin capsule Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- 235000010980 cellulose Nutrition 0.000 claims description 5
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 5
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 4
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 4
- 150000002338 glycosides Chemical class 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 3
- 229930182470 glycoside Natural products 0.000 claims description 3
- 229960004488 linolenic acid Drugs 0.000 claims description 3
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 238000001125 extrusion Methods 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000009478 high shear granulation Methods 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 238000005550 wet granulation Methods 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims 4
- 229930003231 vitamin Natural products 0.000 claims 4
- 235000013343 vitamin Nutrition 0.000 claims 4
- 239000011782 vitamin Substances 0.000 claims 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims 3
- 230000003014 reinforcing effect Effects 0.000 claims 2
- SBHCLVQMTBWHCD-METXMMQOSA-N (2e,4e,6e,8e,10e)-icosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C(O)=O SBHCLVQMTBWHCD-METXMMQOSA-N 0.000 claims 1
- HXWJFEZDFPRLBG-UHFFFAOYSA-N Timnodonic acid Natural products CCCC=CC=CCC=CCC=CCC=CCCCC(O)=O HXWJFEZDFPRLBG-UHFFFAOYSA-N 0.000 claims 1
- 239000012674 herbal formulation Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 10
- 102000004067 Osteocalcin Human genes 0.000 description 8
- 108090000573 Osteocalcin Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 206010030247 Oestrogen deficiency Diseases 0.000 description 7
- 230000009469 supplementation Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 235000014106 fortified food Nutrition 0.000 description 5
- 208000006386 Bone Resorption Diseases 0.000 description 4
- 206010065687 Bone loss Diseases 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229930012930 isoflavone derivative Natural products 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 108010093329 antihemorrhagic factor Proteins 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- MBMBGCFOFBJSGT-SFGLVEFQSA-N docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C\C\C=C\C\C=C\C\C=C\C\C=C\C\C=C\CCC(O)=O MBMBGCFOFBJSGT-SFGLVEFQSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Birds (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
(a) 1종 이상의 이소플라본 및/또는 이소플라본 글리코시드, 바람직하게는 제니스테인 및/또는 제니스틴;
(b) 1종 이상의 다가 불포화 지방산,
(c) 선택적으로, 비타민 D 및/또는 이의 1종 이상의 유도체 및/또는 비타민 K 및/또는 이의 1종 이상의 유도체; 및
(d) 선택적으로, 필요량, 바람직하게는 조성물의 총 중량을 기준으로 0.1 내지 20 중량%의 보조제 및 부형제
를 포함함을 특징으로 하는, 골다공증을 예방하는 데 유용한 조성물에 관한 것이다.
Claims (32)
- (a) 다이드제인, 다이드제인 글리코시드, 글리사이테인, 글리사이테인 글리코시드, 제니스테인 및 제니스테인 글리코시드로 구성된 군에서 선택된 이소플라본 또는 이소플라본 글리코시드, 또는 이들의 혼합물;(b) 다수의 불포화 탄소-탄소 이중 결합을 포함하는 탄소수 16 내지 24개의 다가 불포화 지방산; 및(c) 비타민 D, 비타민 K 및 이들의 혼합물로 구성된 군에서 선택된 비타민의 혼합물을 포함하는 골다공증 예방용 조성물.
- 제 1 항에 있어서,비타민 D의 농도가 1일 당 5 내지 50㎍의 비타민 D가 소비되게 하는 농도이고, 비타민 K의 농도가 1일 당 0.050 내지 10mg의 비타민 K가 소비되게 하는 농도인, 조성물.
- 제 1 항에 있어서,조성물의 총 중량을 기준으로 0.1 내지 20 중량%의 양으로 보조제 및 부형제를 추가로 포함하는 조성물.
- 제 1 항에 있어서,성분 (a)가 제니스테인, 제니스틴 또는 이들의 혼합물인, 조성물.
- 제 1 항에 있어서,성분 (b)가 탄소수 18 내지 22개의 다가 불포화 지방산인, 조성물.
- 제 5 항에 있어서,다가 불포화 지방산이 n-3 다가 불포화 지방산인, 조성물.
- 제 1 항에 있어서,성분 (b)가 리놀레산, 리놀렌산, 에이코사테트라엔산, 에이코사펜타엔산 및 도코사헥사엔산으로 구성된 군에서 선택되는, 조성물.
- 제 1 항에 있어서,성분 (b)가 (시스,시스,시스-)9,12,15-옥타데카트리엔산, (시스,시스,시스-)6,9,12-옥타데카트리엔산, (시스-)5,8,11,14-에이코사테트라엔산, (시스-)5,8,11,14,17-에이코사펜타엔산 및 (시스-)4,7,10,13,16,19-도코사헥사엔산으로 구성된 군에서 선택되는, 조성물.
- 제 1 항에 있어서,다가 불포화 지방산이 1일 소비량이 50 내지 8000mg이 되게 하는 농도로 존재하는, 조성물.
- 제 1 항에 있어서,성분 (a) 1mg 당 5 내지 200mg의 성분 (b)를 포함하는 조성물.
- 제 1 항에 있어서,비타민이 비타민 D3, 비타민 K1 및 이들의 혼합물로 구성된 군에서 선택되는, 조성물.
- 제 11 항에 있어서,비타민 D3의 농도가 1일 당 5 내지 50㎍의 비타민 D3이 소비되게 하는 농도이고, 비타민 K1의 농도가 1일 당 0.050 내지 10mg의 비타민 K1이 소비되게 하는 농도인, 조성물.
- 제 3 항에 있어서,보조제 및 부형제가 전분, 전분 유도체, 셀룰로스, 셀룰로스 유도체, 폴리올 및 이들의 혼합물로 구성된 군에서 선택되는, 조성물.
- 제 13 항에 있어서,셀룰로스 유도체가 하이드록시프로필메틸셀룰로스[HPMC], 메틸셀룰로스[MC] 또는 이들의 혼합물인, 조성물.
- 제 1 항에 있어서,농축물, 과립, 정제, 경질 또는 연질 젤라틴 캡슐에 충전된 페이스트(paste) 및 발포성 제제로 구성된 군에서 선택된 형태로 제공되는 조성물.
- 제 15 항에 있어서,성분들의 단순 분말 혼합물인 농축물 형태의 조성물.
- 제 15 항에 있어서,유동화층 과립화, 고전단 과립화, 압출 성형, 분무 건조 또는 습식 과립화에 의해 수득되는 분말 또는 과립 형태의 조성물.
- 삭제
- 조성물의 총 중량을 기준으로 0.1 내지 20 중량%의 양으로 제 1 항에 정의된 바와 같은 성분 (a), 성분 (b) 및 성분 (c)의 혼합물로 구성된 조성물을 포함하는, 보강 식품, 보강 사료 또는 음료 형태의 식이 조성물.
- 제 1 항 내지 제 17 항중 어느 한 항의 조성물을 포함하는, 정제, 과립, 경질 또는 연질 젤라틴 캡슐에 충전된 페이스트, 또는 발포성 제제 형태의 생약 제제.
- 제 1 항에 있어서,포유 동물에서 골다공증을 예방하거나 치료하거나, 또는 골 형성을 자극하는 데 사용하기 위한 조성물.
- 제 1 항 내지 제 17 항중 어느 한 항의 조성물 유효량을 인간을 제외한 포유 동물에게 투여함을 포함하는, 인간을 제외한 포유 동물에서 골다공증을 예방하거나 골 형성을 자극하는 방법.
- 삭제
- 삭제
- (a) 1일 당 5 내지 100mg이 소비되게 하는 농도의 제니스테인;(b) 리놀레산, 리놀렌산, 에이코사테트라엔산, 에이코사펜타엔산 및 도코사헥사엔산으로 구성된 군에서 선택된 다가 불포화 지방산;(c) 1일 당 5 내지 50㎍이 소비되게 하는 농도의, 비타민 D, 비타민 D3 및 이들의 혼합물로 구성된 군에서 선택된 비타민; 및(d) 1일 당 0.050 내지 10mg이 소비되게 하는 농도의, 비타민 K, 비타민 K1 및 이들의 혼합물로 구성된 군에서 선택된 비타민을 포함하는, 포유 동물에서 골다공증을 예방하거나 치료하거나, 또는 골 형성을 자극하는 데 사용하기 위한 조성물.
- 제 19 항에 있어서,포유 동물에서 골 무기질 밀도의 손실을 예방하거나 골 형성을 자극하는 데 사용하기 위한 식이 조성물.
- 제 20 항에 있어서,포유 동물에서 골다공증을 예방하거나 치료하거나, 또는 골 형성을 자극하는 데 사용하기 위한 생약 제제.
- 제 1 항에 있어서,성분 (b)가 탄소수 18, 20 또는 22개의 다가 불포화 지방산인, 조성물.
- 제 1 항에 있어서,다가 불포화 지방산이 1일 소비량이 500 내지 2000mg이 되게 하는 농도로 존재하는, 조성물.
- 제 1 항에 있어서,성분 (a) 1mg 당 20 내지 50mg의 성분 (b)를 포함하는 조성물.
- 제 2 항 또는 제 12 항에 있어서,비타민 K 및 비타민 K1의 농도가 1일 당 각각 0.1 내지 1.0mg의 비타민 K 및 비타민 K1이 소비되게 하는 농도인, 조성물.
- 제 25 항에 있어서,조성물의 총 중량을 기준으로 0.1 내지 20 중량%의 양으로 보조제 및 부형제를 추가로 포함하는 조성물.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01106520 | 2001-03-15 | ||
EP01106520.8 | 2001-03-15 | ||
PCT/EP2002/002646 WO2002074308A1 (en) | 2001-03-15 | 2002-03-11 | Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040025906A KR20040025906A (ko) | 2004-03-26 |
KR100875800B1 true KR100875800B1 (ko) | 2008-12-24 |
Family
ID=8176795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020037012046A KR100875800B1 (ko) | 2001-03-15 | 2002-03-11 | 이소플라본과 다가 불포화 지방산의 혼합물을 포함하는골다공증 예방용 조성물 |
Country Status (12)
Country | Link |
---|---|
US (1) | US7635692B2 (ko) |
EP (3) | EP1370257B1 (ko) |
JP (1) | JP4646491B2 (ko) |
KR (1) | KR100875800B1 (ko) |
CN (1) | CN100389765C (ko) |
AT (1) | ATE367810T1 (ko) |
BR (1) | BRPI0208103B8 (ko) |
CA (1) | CA2440261C (ko) |
DE (1) | DE60221367T2 (ko) |
ES (1) | ES2289097T3 (ko) |
MX (1) | MXPA03008137A (ko) |
WO (1) | WO2002074308A1 (ko) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003207429A1 (en) * | 2002-02-15 | 2003-09-04 | N.V. Nutricia | Use of genistein in the manufacture of a medicament for the treatment of osteoporosis and obesity, and compositions containing genistein in combination with vitamin d and k |
ITMI20022723A1 (it) * | 2002-12-20 | 2004-06-21 | Marfarma S R L Ora Marfarma Holding Spa | Composizioni per il trattamento della sindrome post-menopausa. |
PL1732605T3 (pl) * | 2004-03-29 | 2019-09-30 | Wyeth Llc | Multiwitaminowe i mineralne suplementy odżywcze |
CN100351248C (zh) * | 2004-07-05 | 2007-11-28 | 南京大学 | 染料木素衍生物及其制法和用途 |
US7601370B2 (en) | 2004-07-28 | 2009-10-13 | Abbott Laboratories | Method for controlling body weight in estrogen-insufficient women |
JP5566008B2 (ja) * | 2005-02-15 | 2014-08-06 | ディーエスエム アイピー アセッツ ビー.ブイ. | 多糖類含有組成物 |
WO2006088418A1 (en) * | 2005-02-18 | 2006-08-24 | Core Competence Sweden Ab | A composition comprising a powder containing microencapsulated polyunsaturated long-chain esterified fatty acids distributed in an effervescent base |
EP1993579A2 (en) * | 2006-02-28 | 2008-11-26 | Council of Scientific and Industrial Research | A pharmaceutical composition for the prevention/treatment of bone disorders and a process for the preparation thereof |
WO2007100671A2 (en) * | 2006-02-28 | 2007-09-07 | Nestec S.A. | Compositions and methods for inducing bone growth and inhibiting bone loss |
EP2004169B1 (en) | 2006-04-12 | 2012-08-08 | Unilever PLC | Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin |
WO2007116052A1 (en) * | 2006-04-12 | 2007-10-18 | Unilever Plc | Oral composition comprising dha and genistein for enhancing skin properties |
PL2189155T3 (pl) * | 2006-04-12 | 2016-07-29 | Unilever Nv | Doustna kompozycja o przeciwstarzeniowym działaniu na skórę |
WO2007128461A1 (en) * | 2006-05-10 | 2007-11-15 | Dsm Ip Assets B.V. | Animal food composition comprising genistein and polyunsaturated fatty acids |
US20070298079A1 (en) * | 2006-06-26 | 2007-12-27 | Tropicana Products, Inc. | Food fortified with omega-3 fatty acids |
JP5827784B2 (ja) * | 2006-07-14 | 2015-12-02 | ナットファルマ エーエスエー | ビタミンk2を含む医薬及び栄養補助製品 |
EP1897530A1 (en) * | 2006-09-08 | 2008-03-12 | DSMIP Assets B.V. | Skin care composition |
EP2129373B1 (en) * | 2007-04-02 | 2013-05-22 | DSM IP Assets B.V. | Use of genistein for treating dry eye syndrome |
US8211947B2 (en) * | 2008-01-28 | 2012-07-03 | Guillermo Selman-Housein Sosa | Composition and method for treating and preventing musculoskeletal and connective tissue disorders |
CN101537170B (zh) * | 2008-03-17 | 2012-05-30 | 哈药集团制药六厂 | 一种预防骨质疏松和骨关节病的组合物 |
CN101574338B (zh) * | 2008-05-05 | 2012-01-11 | 上海医药工业研究院 | 一种抑制芳香化酶活性的药物组合物及其应用 |
CA2726662C (en) | 2008-06-03 | 2016-02-02 | John Ray Biffin | A method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin k |
TR201004464A2 (tr) * | 2010-06-03 | 2012-11-21 | B�Lg�� Mahmut | Kemik erimesi için formülasyon. |
CN102356877A (zh) * | 2011-10-14 | 2012-02-22 | 李泼 | Cbp养钙冲剂 |
WO2013089654A1 (en) * | 2011-12-16 | 2013-06-20 | Mahmut Bilgic | Effervescent formulations comprising genistein |
FR3005419B1 (fr) | 2013-05-13 | 2015-09-04 | Agronomique Inst Nat Rech | Utilisation d'une association de deux composes pour le traitement et/ou la prevention de troubles osseux |
WO2016099495A1 (en) * | 2014-12-17 | 2016-06-23 | Hill's Pet Nutrition, Inc. | Method and composition for reducing hyperthyroidism |
CN109527538A (zh) * | 2018-11-07 | 2019-03-29 | 云南金霓尔生物科技有限公司 | 一种治疗骨质疏松促进吸收的营养剂及其制备方法 |
CN112401066B (zh) * | 2020-11-18 | 2022-10-28 | 乖宝宠物食品集团股份有限公司 | 一种利于维持骨骼健康的宠物食品 |
CN112790278B (zh) * | 2021-01-22 | 2022-10-28 | 乖宝宠物食品集团股份有限公司 | 一种维持骨骼健康的全价宠物罐头食品 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04253908A (ja) * | 1990-12-28 | 1992-09-09 | Nippon Oil & Fats Co Ltd | 骨粗鬆症治療薬 |
GB9112052D0 (en) * | 1991-06-05 | 1991-07-24 | Efamol Holdings | Fatty acid treatment |
GB9217780D0 (en) * | 1992-08-21 | 1992-10-07 | Efamol Holdings | Fatty acid treatment |
DE19503190A1 (de) * | 1995-02-01 | 1996-08-08 | Dietl Hans | Mittel zur Beeinflussung von Störungen der Knochenbildung |
JP3250071B2 (ja) * | 1997-06-26 | 2002-01-28 | 株式会社ホーネンコーポレーション | 抗骨粗鬆症組成物 |
IT1299191B1 (it) * | 1998-06-23 | 2000-02-29 | Sigma Tau Healthscience Spa | Composizione atta a prevenire e trattare l'osteoporosi e le alterazioni legate alla menopausa |
US6150399A (en) * | 1998-06-30 | 2000-11-21 | Abbott Laboratories | Soy-based nutritional products |
JP2000191526A (ja) * | 1998-12-25 | 2000-07-11 | Marumiya:Kk | 骨形成促進及び抗骨粗鬆症組成物 |
AU4402600A (en) * | 1999-05-18 | 2000-12-05 | Rawlings, Anthony V. | Fat containing products |
FR2817866B1 (fr) * | 2000-12-13 | 2005-01-07 | Theramex | Procede d'extraction de melanges flavoniques et utilisation des melanges ainsi obtenus en dermocosmetique, en alimentation et en pharmacie |
-
2002
- 2002-03-11 JP JP2002573015A patent/JP4646491B2/ja not_active Expired - Fee Related
- 2002-03-11 WO PCT/EP2002/002646 patent/WO2002074308A1/en active IP Right Grant
- 2002-03-11 EP EP02726156A patent/EP1370257B1/en not_active Expired - Lifetime
- 2002-03-11 BR BR0208103-2 patent/BRPI0208103B8/pt not_active IP Right Cessation
- 2002-03-11 US US10/471,890 patent/US7635692B2/en not_active Expired - Fee Related
- 2002-03-11 EP EP07014076A patent/EP1852115A1/en not_active Withdrawn
- 2002-03-11 DE DE60221367T patent/DE60221367T2/de not_active Expired - Lifetime
- 2002-03-11 CA CA2440261A patent/CA2440261C/en not_active Expired - Lifetime
- 2002-03-11 ES ES02726156T patent/ES2289097T3/es not_active Expired - Lifetime
- 2002-03-11 AT AT02726156T patent/ATE367810T1/de not_active IP Right Cessation
- 2002-03-11 EP EP07014063A patent/EP1854462A1/en not_active Withdrawn
- 2002-03-11 CN CNB028066634A patent/CN100389765C/zh not_active Expired - Fee Related
- 2002-03-11 KR KR1020037012046A patent/KR100875800B1/ko active IP Right Grant
- 2002-03-11 MX MXPA03008137A patent/MXPA03008137A/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
BRPI0208103B1 (pt) | 2018-02-14 |
US20040082523A1 (en) | 2004-04-29 |
EP1852115A1 (en) | 2007-11-07 |
EP1370257A1 (en) | 2003-12-17 |
EP1370257B1 (en) | 2007-07-25 |
KR20040025906A (ko) | 2004-03-26 |
MXPA03008137A (es) | 2003-12-12 |
DE60221367T2 (de) | 2008-04-03 |
EP1854462A1 (en) | 2007-11-14 |
CN1501799A (zh) | 2004-06-02 |
WO2002074308A1 (en) | 2002-09-26 |
JP4646491B2 (ja) | 2011-03-09 |
BR0208103A (pt) | 2004-03-02 |
CA2440261A1 (en) | 2002-09-26 |
BRPI0208103B8 (pt) | 2021-05-25 |
JP2004532829A (ja) | 2004-10-28 |
US7635692B2 (en) | 2009-12-22 |
DE60221367D1 (de) | 2007-09-06 |
ES2289097T3 (es) | 2008-02-01 |
CN100389765C (zh) | 2008-05-28 |
CA2440261C (en) | 2014-05-27 |
ATE367810T1 (de) | 2007-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100875800B1 (ko) | 이소플라본과 다가 불포화 지방산의 혼합물을 포함하는골다공증 예방용 조성물 | |
US6359017B1 (en) | Dietary compositions and methods | |
SK19292000A3 (sk) | Kompozícia na prevenciu a/alebo liečenie osteoporózy a zmien v dôsledku menopauzálneho syndrómu | |
KR20080068850A (ko) | 레스베라트롤을 포함하는 기능성식품 조성물의 신규한 용도 | |
EP1988891B1 (en) | Compositions and methods for inducing bone growth and inhibiting bone loss | |
JP4447913B2 (ja) | オステオポローシス治療のための組成物の製造のためのグルタミン酸塩、グルタミン酸塩誘導体又はグルタミン酸塩代謝物、グルタミン酸塩アナログ或いはそれらの混合物の使用 | |
JP4714343B2 (ja) | 骨吸収増加治療用の植物抽出物 | |
Pointillart et al. | Meal-feeding and phosphorus ingestion influence calcium bioavailability evaluated by calcium balance and bone breaking strength in pigs | |
Dalderup | Nutrition and Caries: IX. the Influence of Calcium Carbonate On Rat Caries Induced By a Cariogenic Diet | |
CN115038435A (zh) | 肥胖抑制用组合物 | |
EP2052721A1 (en) | Use of carnosol for cartilage repair | |
JP2002058452A (ja) | 骨密度改善機能を有するカルシウム含有食品組成物 | |
JPH10513061A (ja) | 1α−ヒドロキシル化ビタミンD化合物含有低リン動物用飼料 | |
Okafor et al. | A Comparative Study of the Ameliorative Effects of Skimmed Milk and Tuna Fish in the Dietary Management of Dexamethasone Sodium Phosphate Induced Osteoporotic Female Wistar Rats | |
EP1180331A1 (en) | Blends of isoflavones and flavones | |
WO2023069475A1 (en) | Chondroprotective nutraceutical composition and method of using same | |
AU2007221221B2 (en) | Compositions and methods for inducing bone growth and inhibiting bone loss | |
Elkins | Genistein | |
MX2008010657A (en) | Compositions and methods for inducing bone growth and inhibiting bone loss |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
N231 | Notification of change of applicant | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121123 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20131119 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20141126 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20151118 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20161123 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20171117 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20181115 Year of fee payment: 11 |